Chengdu Kanghua Biological Products (300841.SZ): ACYW135 Meningococcal Conjugate Vaccine Obtains Clinical Trial Approval Letter
Kanghua Biological (300841.SZ) announced that recently, the company's research and development of ACYW135 group A. meningococcal meningitis conjugate vaccine has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing clinical trials of the vaccine to be conducted.
Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company's research and development of ACYW135 group meningococcal conjugate vaccine has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the clinical trial of the vaccine.
According to the "Drug Administration Law of the People's Republic of China", the "Vaccine Administration Law of the People's Republic of China" and relevant regulations, after review, the ACYW135 group meningococcal conjugate vaccine accepted on December 12, 2025 meets the requirements for drug registration, and is approved to conduct clinical trials for the prevention of epidemic meningitis caused by group A, C, Y, and W135 meningococcal.
Related Articles
Qingdao TGOOD Electric (300001.SZ) won the bid for the Qinghai Oilfield Wind Power Project with a contract value of approximately 150 million yuan.
Giantec Semiconductor Corporation (688123.SH): Beijing Luojia plans to reduce its stake in the company by no more than 2.61%.
Revenue and profits doubled, and the dividend yield exceeded 4%, how about the value for LEE & MAN PAPER (02314)?
Qingdao TGOOD Electric (300001.SZ) won the bid for the Qinghai Oilfield Wind Power Project with a contract value of approximately 150 million yuan.
Giantec Semiconductor Corporation (688123.SH): Beijing Luojia plans to reduce its stake in the company by no more than 2.61%.
Revenue and profits doubled, and the dividend yield exceeded 4%, how about the value for LEE & MAN PAPER (02314)?
